When I was getting started in this industry, I did what a lot of people do when they cannot get a foot in the door at the big companies: I found the small ones. Independent distributors carrying products from companies most people had never heard of. Niche devices, small product portfolios, and modest paychecks. But it was the med device industry, and I was in it.

Of course, there was an upside to working with smaller companies. You learned fast, you owned your territory, and you had a direct line to the people who actually made the product. You could also pick up other small product lines and start building yourself a nice business. Nobody was managing you from a corporate office in Memphis or Warsaw. You had to figure things out on your own.

The downside was just as real. The moment one of those small companies started gaining traction, the phone would ring, and it would not be them calling you. It would be someone from a larger company who had just written a check. Suddenly, the product you had been selling, the relationships you had built around it, the surgeons who had come to trust you with it, all of that went to the rep already working for the acquiring company. You were out. Not because you did anything wrong. Because the industry consolidated around you.

I went through that more than once. And every time, I understood the business logic. That did not make it any easier.

That experience is exactly why this week's edition of The Modern Med Rep feels personal. The M&A wave reshaping medtech in 2026 is not just a financial story. It is a career story. Whether you are trying to break in or already building your territory, knowing how consolidation works and how to use it to your advantage can make a real difference in where you end up.

Glad you're here. Let's get into it.

Andy Knapik, Founder

The Modern Med Rep

The $36.5 billion in medtech M&A recorded in the first half of 2026 is not just a financial headline. It is a signal about where the industry is heading, which technologies companies believe will matter most in the next decade, and where commercial opportunity is likely to concentrate as portfolios get reshaped.

Understanding why companies make acquisitions, and what typically happens after, is knowledge that belongs in every device professional's toolkit, whether you're trying to break in or already building a territory.

Why companies buy.  Most medtech acquisitions fall into one of three categories. The first is technology acceleration: buying a company to gain access to a product, platform, or capability that would take years and significant capital to develop internally. Boston Scientific's acquisition of Penumbra is a textbook example, adding a neurovascular clot-removal portfolio that BSC could not have competitively built from scratch. The second is market entry: moving into an adjacent category to diversify revenue or reduce dependence on a maturing segment. The third is scale: buying volume in a market where the company already competes, to strengthen its negotiating position with hospitals and GPOs. All three create commercial activity in their wake.

What happens to commercial teams after a deal? The pattern is fairly consistent. In the months following an acquisition, the acquiring company typically conducts an assessment of the combined commercial infrastructure. Redundant territories get consolidated. Strong performers from both organizations get retained and often promoted to lead the integrated team. Roles that did not exist before the deal get created, particularly where the acquiring company is entering new clinical territory and needs people who understand both the technology and the customer relationships. This is where the opportunity lies for anyone paying attention.

The deals creating the most commercial activity right now. Boston Scientific's acquisition of Penumbra will require building neurovascular commercial infrastructure at scale. Abbott's integration with Exact Sciences is driving significant hiring in oncology diagnostics. Medtronic's acquisition of SPR Therapeutics for $650 million adds peripheral nerve stimulation to its neuromodulation portfolio and will need a commercial team to match. Danaher's $9.9 billion acquisition of Masimo brings patient monitoring into a company that previously focused on life sciences, creating an entirely new commercial motion. Each of these deals is in various stages of integration, and each one represents a window of opportunity for device professionals who understand the acquired technology and the clinical environments it serves.

What M&A means for the innovation pipeline. One consequence of sustained M&A activity worth tracking is the impact on the startup ecosystem. PwC's midyear analysis noted that venture capital funding for medtech startups remains constrained and the IPO market is inconsistent, limiting traditional exit pathways. That means fewer well-funded early-stage companies and more pressure on established players to innovate through acquisition rather than internal development. For device professionals, this has a practical implication: the companies most likely to be building new commercial teams are the large acquirers, not the startups. The growth opportunity is concentrated inside companies that are actively reshaping their portfolios.

Most people watch medtech acquisitions as industry news. The people who get ahead treat them as a job market signal. Here's how to actually use M&A activity to your advantage, whether you're trying to break in or are already in the industry, looking for your next move.

Watch for the integration window. The 6 to 18 months following a major acquisition is typically when the most commercial restructuring happens. Companies assess what they have, consolidate what is redundant, and build what is missing. This is when new roles appear, territories get redrawn, and leadership positions open up across both the acquiring and acquired organizations. If a company you are targeting has recently completed a significant acquisition, that is a compelling reason to accelerate your outreach.

Target the technology, not just the company. When Boston Scientific acquires Penumbra, it is not just hiring for Boston Scientific roles. It is hiring for the Penumbra portfolio. The clinical specialists who understand thrombectomy devices, the territory managers who have relationships with interventional neurologists and vascular surgeons, the clinical educators who can train hospital teams on clot-removal workflows. Understanding what was acquired, what it does, and who the clinical customer is gives you a targeting advantage that most candidates do not have.

Divestitures create opportunity too.  When J&J spins off DePuy Synthes, when Medtronic completes its MiniMed diabetes spinoff, when a large company sells a division to private equity, the resulting standalone entity typically needs to rebuild infrastructure it previously shared with its parent. Finance, compliance, marketing, and commercial leadership all need to be staffed. Standalone orthopedics companies, diagnostics businesses, and neuromodulation platforms that emerge from divestitures often hire aggressively in their first year of independence.

Where to focus right now.  Based on current deal activity, the segments generating the most integration-driven hiring are neurovascular (Boston Scientific and Penumbra), oncology diagnostics (Abbott and Exact Sciences), neuromodulation (Medtronic and SPR Therapeutics), and patient monitoring (Danaher and Masimo). In orthopedics, the DePuy Synthes spinoff process will generate significant hiring over the next 18 to 24 months. Anyone with clinical or commercial experience in any of these areas should be building relationships inside these organizations now, before the roles are posted.

The AcuityMD benchmark finding is worth sitting with for a moment. Device reps who use AI are three times more likely to hit quota. That is not a marginal difference. It is a structural advantage that is growing as early adopters build competency and the tools themselves improve.

What AI is actually doing for reps right now is less dramatic than the headline suggests, but more practically useful than most people realize. The primary applications are in account prioritization, call planning, and territory intelligence. Tools like AcuityMD, MedScout, Alpha Sophia and SmartTRAK pull together FDA procedure data, claims data, physician profiles, and facility information to help companies identify which accounts have the highest procedure volume and the greatest fit for their product, without spending hours doing manual research. The reps who save four to six hours a week are not doing anything exotic. They are automating the research work that used to eat into selling time.

The gap between AI users and non-users matters for two reasons beyond quota attainment. First, as more reps adopt these tools, the baseline expectation for territory preparation and account knowledge will rise. The rep who shows up with a general sense of a hospital's procedure volume will increasingly be out-prepared by the one who has analyzed the facility's claims data, physician referral patterns, and payer mix before walking in the door. Second, the companies selling into medtech are investing heavily in AI-powered commercial platforms. Familiarity with these tools is becoming part of the job description at forward-leaning organizations.

For anyone breaking in: understanding that AI tools exist and knowing what they do puts you ahead of most candidates. For anyone already in med device: if you are not using AI in your territory planning, the data suggests you are leaving quota attainment on the table.

This week's question is one that comes up a lot in the context of M&A:

Have a question? Reply to this email. The best ones make it into the next issue.

QUOTE OF THE WEEK

“In the middle of every difficulty lies opportunity.”

- Albert Einstein